Syngene International Ltd. News and Updates

Name: Latest research reports of Syngene International Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Syngene International Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news on Syngene International Ltd. from all sources in a single place.

Load latest

Syngene International Ltd.

19 Oct 2022

724.15

0.84%

to see Rapid results content

Syngene International Ltd.

06 Sep 2022

724.15

0.84%

Syngene trades weak after nearly 6% equity changes hands via block deals

Business Standard

At 09:15 am; around 22.68 million equity shares representing 5.65 per cent of the total equity of Syngene changed hands on the BSE, the exchange data shows.

Number of FII/FPI investors increased from 337 to 359 in Dec 2024 qtr.

Syngene International Ltd.

22 Jul 2022

724.15

0.84%

Syngene International Ltd

Buy: Syngene International Ltd.

Target

ICICI Direct

Syngene International Ltd. is trading above its 50 day SMA of 718.6

Syngene International Ltd.

20 Jul 2022

724.15

0.84%

Syngene International Q1 PAT slips 4% to Rs 74 cr; revenue rises 8%

Business Standard

Contract manufacturing services firm Syngene International on Wednesday reported a 4 per cent decline in profit after tax to Rs 74 crore for the first quarter ended June 2022. The company had posted a PAT of Rs 77 crore in the April-June quarter of last fiscal. Its revenue from operations rose to Rs 644 crore in the first quarter against Rs 595 crore in the year-ago period, the company said in a statement. The first quarter results were against a strong quarter last year due to sales of Remdesivir, it added. Excluding the impact of Remdesivir, the underlying revenue from operations growth in the quarter stood at around 30 per cent year-on-year, it stated. "The first quarter results were in line with our expectations and reflect strong underlying performance across all our business divisions. The contribution from the development and manufacturing services divisions drove the growth momentum against a low base in the previous year," Syngene International MD and CEO Jonathan Hunt ..

Syngene International Ltd. has lost -20.36% in the last 6 Months

Syngene raises full-year revenue guidance despite dip in PAT by 4% in Q1

Business Line | 20 Jul 2022

Syngene International Ltd.

20 Jul 2022

724.15

0.84%

to see Rapid results content

Syngene International Ltd.

17 Jul 2022

724.15

0.84%

Deal with Zoetis could be worth $500 mn in 10 yrs: Syngene In'l chief

Business Standard

In a Q&A, Jonathan Hunt, MD & CEO of the Biocon arm, dwells on his firm's initiatives to overcome supply chain bottlenecks and other issues

Syngene International Ltd.'s price crossed above 50Day SMA today

Syngene International Ltd.

15 Jul 2022

724.15

0.84%

Syngene International signs 10-year agreement with US-based firm Zoetis

Business Standard

Librela or bedinvetmab has already been launched in Europe and the UK, and has won 'Best new companion animal product' by IHS Markit Connect in 2021

Syngene International Ltd. is trading above its 50 day SMA of 718.6

Syngene inks 10-year biologics manufacturing pact with Zoetis

Business Line | 14 Jul 2022

Syngene International Ltd.

06 May 2022

724.15

0.84%

Seeing good demand for chemistry, biology'

livemint

Q4 growth was driven by solid delivery across all 4 divisions: Syngene's CEO

Syngene International Ltd. has lost -20.36% in the last 6 Months

Syngene International Ltd.

30 Apr 2022

724.15

0.84%

Buy Syngene International; target of Rs 730: ICICI Direct

Moneycontrol

ICICI Direct is bullish on Syngene International has recommended buy rating on the stock with a target price of Rs 730 in its research report dated April 29, 2022.

Syngene International Ltd. has lost -20.36% in the last 6 Months

No results found

Is Syngene International Ltd. worth buying?

228 Votes:

Buy 75.44%

Sell 14.91%

Hold 9.65%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf